{{item.title}}
{{item.text}}
{{item.title}}
{{item.text}}
Pharmaceutical and life sciences
Helping clients better compete in an evolving health market and improve cost-efficiency and profitability
Top health industry issues of 2019: The New Health Economy comes of age
The US health industry has often lagged other industries when it comes to modernizing. Once thought to operate outside the greater US economy, the industry—with its byzantine payment system, complicated regulatory barriers and reliance on face-to-face interactions—is being disrupted. Finally, there’s robust evidence that what PwC calls the New Health Economy is kicking into gear.
The potential impact of tax reform on pharmaceutical and life sciences companies
From President Trump's tax plan to healthcare reform—we break down developments from Washington and what companies in our industry need to do to anticipate and prepare for legislative change.
{{filterContent.facetedTitle}}
{{contentList.dataService.numberHits}} {{contentList.dataService.numberHits == 1 ? 'result' : 'results'}}
{{contentList.loadingText}}
{{contentList.loadingText}}
Contact us
Douglas Strang
Global Pharmaceutical and Life Sciences Advisory Leader, PwC US
Tel: +1 (267) 330 3045
Glenn Hunzinger
US Pharmaceutical and Life Sciences Deals Leader, PwC US
Tel: +1 (646) 818 7742
Follow us
